Microbiology Testing Market: By Product Type (Instruments, Chemicals & Reagents, Consumables & Accessories, Others), By Application (Gastrointestinal Infections, Respiratory Infections, Urinary Tract Infections, Bloodstream Infections, Sexually Transmitted Infections, Others), By End-User (Hospital Based Laboratories, Independent Laboratories, Academics & Research Institutes, Others) and Geography

Microbiology Testing Market size was valued at USD 3,913.6 million in 2022 and is poised to grow at a significant CAGR of 10.6% from 2023-2029. Microbiology testing is an analytical technique utilized to determine the number of microorganisms in psoriasis biologicals samples, food, beverages, and environmental samples. The microbiology testing technique employs chemical, biological, biochemical, or molecular methods to identify and quantify microbes. The Chemicals & Reagents segment is anticipated to grow at a significant CAGR over the forecast years owing to the wide range of chemical reagent uses and research activities Constant advancements and development in technologies such as bio-therapeutics, cell culture, and recombinant DNA technology, which have allowed the manufacturers of a wide range of vital therapeutic agents, also fuel the demand for laboratory chemical reagents. Furthermore, rising demand from the biotechnology industry may drive market expansion in the next years. The market for protein synthesis and DNA sequencing reagents has grown considerably in recent years. Technological improvements in microbiology testing, increased occurrences of infectious illnesses and epidemic outbreaks such as COVID-19, rising healthcare spending, and expanding private-public financing for infectious disease research are driving the growth of the microbiology testing market.

Microbiology Testing Market Key Developments:

• In February2020, QIAGEN partnered with Nigeria’s National Tuberculosis & Leprosy Control Program (NTBLCP) to adopt the World Health Organization (WHO) guidelines and guide healthcare professionals in dealing with latent TB

• In July 2020, bioMérieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry. The new BIOFIRE MYCOPLASMA test, which is available in the United States, will be launched in some countries in Europe and the Asia-Pacific region in the coming months.